company background image
0OIR logo

ALK-Abelló LSE:0OIR Stock Report

Last Price

kr.128.71

Market Cap

kr.28.3b

7D

-0.5%

1Y

23.1%

Updated

25 Mar, 2024

Data

Company Financials +

0OIR Stock Overview

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally.

0OIR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance4/6
Financial Health6/6
Dividends0/6

ALK-Abelló A/S Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ALK-Abelló
Historical stock prices
Current Share Pricekr.128.71
52 Week Highkr.134.19
52 Week Lowkr.70.40
Beta0.44
1 Month Change0.75%
3 Month Change30.53%
1 Year Change23.12%
3 Year Change9.82%
5 Year Change132.12%
Change since IPO134.40%

Recent News & Updates

Recent updates

Shareholder Returns

0OIRGB PharmaceuticalsGB Market
7D-0.5%1.7%2.4%
1Y23.1%-0.1%4.2%

Return vs Industry: 0OIR exceeded the UK Pharmaceuticals industry which returned -0.1% over the past year.

Return vs Market: 0OIR exceeded the UK Market which returned 4.2% over the past year.

Price Volatility

Is 0OIR's price volatile compared to industry and market?
0OIR volatility
0OIR Average Weekly Movement4.7%
Pharmaceuticals Industry Average Movement9.3%
Market Average Movement4.7%
10% most volatile stocks in GB Market11.3%
10% least volatile stocks in GB Market2.5%

Stable Share Price: 0OIR has not had significant price volatility in the past 3 months.

Volatility Over Time: 0OIR's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19232,824Peter Hallinghttps://www.alk.net

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food.

ALK-Abelló A/S Fundamentals Summary

How do ALK-Abelló's earnings and revenue compare to its market cap?
0OIR fundamental statistics
Market capkr.28.27b
Earnings (TTM)kr.486.00m
Revenue (TTM)kr.4.82b

58.2x

P/E Ratio

5.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0OIR income statement (TTM)
Revenuekr.4.82b
Cost of Revenuekr.1.79b
Gross Profitkr.3.04b
Other Expenseskr.2.55b
Earningskr.486.00m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 03, 2024

Earnings per share (EPS)2.20
Gross Margin62.94%
Net Profit Margin10.07%
Debt/Equity Ratio10.4%

How did 0OIR perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.